Day 1 | Day 2 | Download Brochure<\/p>\n
Tuesday, May 1, 2018<\/p>\n
7:30 am Conference Registration and Continental Breakfast<\/p>\n
8:30 Welcome Keynote and State of the Neurotechnology Industry<\/p>\n
The Neurotechnology Industry Organization and guest speakers provide an annual review of trends and developments in neuropharmaceuticals, neurodevices, and neurodiagnostics.<\/p>\n
Panelists: Alison Fenney, Member, Board of Directors, Neurotechnology Industry Organization<\/p>\n
Harry Tracy, President, NI Research<\/p>\n
James Cavuoto, Editor & Publisher, Neurotech Reports<\/p>\n
9:00 Investing in Neurotech Panel<\/p>\n
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are todays deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?<\/p>\n
Moderator: Joshua Pinto, Vice President, Healthcare Investment Banking, Credit Suisse<\/p>\n
Panelists: Rahul Ballal, Entrepreneur-in-Residence, Versant Ventures<\/p>\n
Laura Tadvalkar, Senior Associate, MP Healthcare Venture Management<\/p>\n
Paulina Hill, Principal, Polaris Partners<\/p>\n
Jamil Beg, Principal, 5AM Ventures<\/p>\n
William Robb, Founding Partner, NovaQuest Capital Management<\/p>\n
10:00 Coffee Break with Exhibit Viewing<\/p>\n
10:40 Treatments for Alzheimers and Cognitive Disorders<\/p>\n
As the population ages, the market for neurodegenerative disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies? Can earlier or more accurate diagnosis improve outcomes?<\/p>\n
Moderator: Michael Gold, Vice President, Development Neurosciences, AbbVie<\/p>\n
Panelists: Christopher U. Missling, President and CEO, Anavex Life Sciences<\/p>\n
Leen Kawas, President and CEO, M3 Biotechnology<\/p>\n
Michael Mullan, CEO, Archer Pharmaceuticals<\/p>\n
Casey Lynch, CEO, Cortexyme<\/p>\n
Carlos Buesa, CEO, Oryzon<\/p>\n
11:40 Developments on the Horizon for Pain and Epilepsy<\/p>\n
Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in treatment resistant populations for epilepsy and neuropathic pain. Hear from leading companies on their approaches.<\/p>\n
Moderator: Robert H. Ring, Founder & President, Auts Consulting and Advisory Solutions<\/p>\n
Panelists: Gregory T. Mayes, President, CEO & Founder, Engage Therapeutics, Inc.<\/p>\n
Stephen Collins, CEO, Biscayne Neurotherapeutics<\/p>\n
Ana Maiques, CEO, NeuroElectrics<\/p>\n
Louis Mayaud, CSO, Mensia Technologies<\/p>\n
12:40 pm Networking Luncheon<\/p>\n
2:00 Internal and External Research and Development<\/p>\n
Pharmaceutical and device companies are looking to provide complete solutions that span from prevention to treatment. Functions across the value chain will be kept in house or partnered. This panel of experts will discuss how they approach collaborations with other companies, academic groups, research institutes, and platform companies.<\/p>\n
Moderator: Christine de los Reyes, Vice President, Strategic Planning & Business Development, Alopexx Enterprises, LLC<\/p>\n
Panelists: Jeff Erb, Senior Director, Strategy and Business Development, Medtronic<\/p>\n
Isaac Veinbergs, Head, External Innovation, Sanofi<\/p>\n
Eric Schaeffer, Senior Director, Neuroscience Innovation, Johnson & Johnson Innovation<\/p>\n
3:00 Refreshment Break with Exhibit Viewing<\/p>\n
3:45Targeting Orphan Diseases<\/p>\n
Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. This session will gather companies developing treatments for ALS, lysosomal storage disorders, Huntingtons, and more.<\/p>\n
Moderator: Daniel Burch, Global Medical Officer, PPD Biotech<\/p>\n
Panelists: Marc Martinell, CEO, Minoryx<\/p>\n
Andrew Lim, CEO, Circumvent Pharmaceuticals <\/p>\n
Lynn Durham, CEO & Founder, Stalicla<\/p>\n
Michael Panzara, Franchise Lead, Neurology, WAVE Life Sciences Ltd. <\/p>\n
Pushkal Garg, Chief Medical Officer, Alnylam Pharmaceuticals<\/p>\n
David B. Clissold, Director, Hyman, Phelps & McNamara, P.C.<\/p>\n
4:45 Strategic Development of Your Product Outside of the US: The Australian Advantage<\/p>\n
Tina Soulis, PhD, CEO, Neuroscience Trials Australia<\/p>\n
This session will focus on case studies to demonstrate the approval process, regulatory framework, tax advantages, networks and overall capabilities that exist in Australia that could be used as part of a strategic development plan to save time, effort and cost when planning your studies.<\/p>\n<\/p>\n
5:00 Emerging Company Showcase - Learn More About Our Participants<\/p>\n
The third annual Emerging Company Showcase offers the stage to young neurotech companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field.<\/p>\n
Moderator: Carla Lema Tome, Advisor, Neurotechnology Industry Organization<\/p>\n
Participants: Lowry Curley, CEO, AxoSim, Inc <\/p>\n
Dan Rizzuto, CEO, Nia Therapeutics<\/p>\n
Shawn Ritchie, CEO and CSO, Med-Life Discoveries LP<\/p>\n
Sefi Epel, CEO, Brainmarc<\/p>\n
Visar Berisha, Co-Founder, CSO, Aural Analytics<\/p>\n
Julie Collens, CEO, Vivid Genomics<\/p>\n
Devon Greco, Founder and CEO, Narbis<\/p>\n
Kumar Sripathirathan, CEO, DEHA<\/p>\n
Steven Prawer, Director, Cofounder, CTO, iBIONICS<\/p>\n
Eliav Shaked, Founder & CEO, RetiSpec<\/p>\n
6:00 Welcome Reception with Exhibit Viewing<\/p>\n
7:00Close of Day<\/p>\n
Day 1 | Day 2 | Download Brochure<\/p>\n
Wednesday, May 2, 2018<\/p>\n
8:00 am Continental Breakfast<\/p>\n
8:45Keynote Presentation<\/p>\n
Stephanie Fertig, MBA, Director, NINDS Small Business Programs, National Institute of Neurological Disorders and Stroke, National Institutes of Health<\/p>\n
9:00 Partnering and Licensing in Neurotech Panel<\/p>\n
Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will discuss their areas of interest for in-licensing novel therapeutics, devices and diagnostics and what they look for in a partner.<\/p>\n
Moderator: John Reppas, Director, Public Policy, Neurotechnology Industry Organization<\/p>\n
Panelists: Murali Gopalakrishnan, Head, Neuroscience Search and Evaluation, AbbVie<\/p>\n
Robert Bagdorf, Vice President, Biopharmaceuticals Search and Evaluation, Pfizer<\/p>\n
Matt Gunderman, Director, Business Development, Boston Scientific<\/p>\n
10:00 Coffee Break with Exhibit Viewing<\/p>\n
10:40 Parkinsons and Other Movement Disorders<\/p>\n
Current treatments for movement disorders can improve functioning, but suffer from side effects and off period, especially as the disease progresses. A number of novel pipeline pharmaceuticals and devices seek to address these issues. This session will explore how disease modifying treatments alter the course of movement disorders, and how companion diagnostics can be leveraged to provide the most optimal outcomes for patients.<\/p>\n
Moderator: Julie G Pilitsis, Chair Dept of Neuroscience & Experimental Therapeutics, Professor of Neurosurgery, Albany Medical College<\/p>\n
Panelists: Ralph Kern, COO and CMO, BrainStorm Therapeutics<\/p>\n
Randall W. Moreadith, CEO, Serina Therapeutics<\/p>\n
Michael Almstetter, CEO, Origenis <\/p>\n
Nader Yaghoubi, President and CEO, PathMaker Neurosystems Inc.<\/p>\n
Jim DeMesa, CEO, Emerald Health Pharmaceuticals<\/p>\n
11:40 Next-Generation Psychiatry<\/p>\n
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market. Development of promising next-generation treatments is challenging. Novel devices and diagnostics are poised to change the treatment landscape. This session will gather the most innovative treatments for mental health disorders.<\/p>\n
Moderator: Manuel Lopez-Figueroa, Venture Partner, Bay City Capital<\/p>\n
Panelists: Remy Luthringer, CEO, Minerva Neurosciences<\/p>\n
Stephen Brannan, CMO, Karuna Pharmaceuticals<\/p>\n
Atul Mahableshwarkar, Vice President, Clinical Development, BlackThorn Therapeutics<\/p>\n
Michael J. Detke, CMO, Embera Therapeutics<\/p>\n
Eric J. Messika, President and CEO, Coronis Neurosciences Ltd.<\/p>\n
12:40 pm Networking Luncheon<\/p>\n
2:00 Frontiers in Neurotechnology<\/p>\n
In this session, we will hear from companies on the cutting edge. Novel neurostimulation devices are being developed for new markets. Closed loop systems create the promise of reduced side effects and more targeted treatment. New technology is yielding benefits in delivery of therapeutics to brain. This session will preview next generation products and companies in neurotechnology.<\/p>\n
Moderator: Daniel OConnell, Founding member & Managing Partner, NeuroVentures; President and Chief Executive Officer, Acumen Pharmaceuticals, Inc.<\/p>\n
<\/p>\n
Go here to read the rest: <\/p>\n
Agenda<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Day 1 | Day 2 | Download Brochure Tuesday, May 1, 2018 7:30 am Conference Registration and Continental Breakfast 8:30 Welcome Keynote and State of the Neurotechnology Industry The Neurotechnology Industry Organization and guest speakers provide an annual review of trends and developments in neuropharmaceuticals, neurodevices, and neurodiagnostics. Panelists: Alison Fenney, Member, Board of Directors, Neurotechnology Industry Organization Harry Tracy, President, NI Research James Cavuoto, Editor & Publisher, Neurotech Reports 9:00 Investing in Neurotech Panel A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded Continue reading